ClinicalTrials.gg
CompletedNCT02890992ODYSSEY KIDSUpdated Sep 6, 2019Results posted

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

A Phase 2 interventional study of alirocumab SAR236553 (REGN727) and statins in Hypercholesterolaemia, sponsored by Sanofi. Completed at 16 sites in 10 countries. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2019-09-06.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
8 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
32nd of 43
42 · median 107
Started
2016
with 4 others
Phase 2
9 of 43
none open now
Registered
32nd of 43
by date
Lead sponsor
28 of 43
Sanofi

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 32nd largest by enrollment, is one of 5 that started in 2016, is one of 9 in phase 2, and was the 32nd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 8 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 8 weeks of treatment in heterozygous familial hypercholesterolemia (heFH) participants aged of 8 to 17 years, with LDL-C >=130 milligrams per deciliter (mg/dL) (3.37 millimoles per litre [mmol/L]) on optimal stable daily dose of statin therapy +/- other lipid modifying therapies (LMTs) or a stable dose of non-statin LMTs in case of intolerance to statins for at least 4 weeks prior to the screening period.

Secondary Objective:

  • To evaluate the safety and tolerability of alirocumab.
  • To evaluate the pharmacokinetics profile of alirocumab.
  • To evaluate the effects of alirocumab on other lipid parameters.
Read the detailed description

For Cohorts 1 to 3, a study duration of approximately 16-23 weeks (screening period: up to 6 (+1) weeks, open-label dose finding treatment period: 8 weeks, follow up period: 6-8 weeks).

For Cohort 4, a study duration of approximately 14-19 weeks (screening period up to 6 [+1] weeks, open-label dose finding treatment period: 12 weeks).

Optional extension period: up to a maximum of 2 years for the first participants enrolled in Cohorts 1 to 3, but a maximum of approximately 5 months for the first participants enrolled in Cohort 4.

For all participants who declined participation in the phase 3 study, their last alirocumab injection was on December 2018.

03

Conditions studied

  • Hypercholesterolaemia
04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and adolescent male and female participants aged of 8 to 17 years at the time of signed . For Russia only: Male and female participants aged >=12 and \<=17 years at the time of signed informed consent.
  • Participants with diagnosis of heterozygous familial hypercholesterolemia (heFH) through genotyping or clinical criteria.
  • Participants treated with optimal dose of statin +/- other LMT(s) or non-statin LMT(s) if statin intolerant at stable dose for at least 4 weeks prior to screening lipid sampling.
  • Participants with calculated LDL-C greater than or equal to 130 mg/dL (>=3.37 mmol/L) at the screening visit.
  • Participants with body weight greater than or equal to 25 kg.
  • Participants aged of 8 to 9 years to be at Tanner stage 1 and participants aged of 10 to 17 years to be at least at Tanner stage 2 in their development.
  • A signed informed consent indicating parental permission with or without participant assent.

Exclusion criteria

Exclusion criteria:

  • Participant with secondary hyperlipidemia.
  • Diagnosis of homozygous familial hypercholesterolemia.
  • Participant who had received lipid apheresis treatment within 2 months prior to the screening period, or has plans to receive it during the study.
  • Known history of type 1 or type 2 diabetes mellitus.
  • Known history of thyroid disease.
  • Known history of hypertension.
  • Fasting triglycerides >350 mg/dL (3.95 mmol/L).
  • Severe renal impairment (i.e., estimated [eGFR] \<30 mL/min/1.73 m\^2).
  • (ALT) or aspartate aminotransferase (AST) >2 x (ULN).
  • Creatinine phosphokinase (CPK) >3 x ULN.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Cohort 1 - Alirocumab 30 mg Q2W: <50 kg

    Period 1: Participants with body weight less than (\<) 50 kilograms (kg) received subcutaneous (SC) injection of alirocumab 30 milligram(mg) administered every 2 weeks (Q2W) up to 8 weeks added to lipid modifying therapy (LMT). Period 2: Participants with body weight \< 50 kg received SC injection of alirocumab 30 mg administered Q2W from Week 16 until they started receiving dose matching to Cohort 2 dosage including dose adjustment to body weight as required. Cohort 2 dosage was: if body weight was still \< 50 kg, participants received SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was \> = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130.

    Drug: alirocumab SAR236553 (REGN727) · Drug: statins · Drug: ezetimibe · Drug: cholestyramine · Drug: fenofibrate · Drug: omega-3 fatty acids · Drug: nicotinic acid

  • Experimental
    Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg

    Period 1: Participants with body weight greater than or equal to (\>=) 50 kg received SC injection of alirocumab 50 mg administered Q2W up to 8 weeks added to LMT. Period 2: Participants with body weight \>= 50 kg received SC injection of alirocumab 50 mg administered Q2W from Week 16 until switch to Cohort 2 dosage then SC injection of alirocumab 75 mg administered Q2W until Week 130.

    Drug: alirocumab SAR236553 (REGN727) · Drug: statins · Drug: ezetimibe · Drug: cholestyramine · Drug: fenofibrate · Drug: omega-3 fatty acids · Drug: nicotinic acid

  • Experimental
    Cohort 2 - Alirocumab 40 mg Q2W: <50 kg

    Period 1: Participants with body weight \< 50 kg received SC injection of alirocumab 40 mg administered Q2W up to 8 weeks added to LMT. Period 2: Participants with body weight \< 50 kg received SC injection of alirocumab 40 mg administered Q2W from Week 16 until switch of dosage in Cohorts 1 and 3. If body weight was still \< 50 kg, participants continued to receive SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was \> = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130.

    Drug: alirocumab SAR236553 (REGN727) · Drug: statins · Drug: ezetimibe · Drug: cholestyramine · Drug: fenofibrate · Drug: omega-3 fatty acids · Drug: nicotinic acid

  • Experimental
    Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg

    Period 1: Participants with body weight \>= 50 kg received SC injection of alirocumab 75 mg administered Q2W up to 8 weeks added to LMT. Period 2: Participants with body weight \>= 50 kg received SC injection of alirocumab 75 mg administered Q2W from Week 16 until Week 130.

    Drug: alirocumab SAR236553 (REGN727) · Drug: statins · Drug: ezetimibe · Drug: cholestyramine · Drug: fenofibrate · Drug: omega-3 fatty acids · Drug: nicotinic acid

  • Experimental
    Cohort 3 - Alirocumab 75 mg Q4W: <50 kg

    Period 1: Participants with body weight \< 50 kg received SC injection of alirocumab 75 mg administered every 4 weeks (Q4W) up to 8 weeks added to LMT. Period 2: Participants with body weight \< 50 kg received SC injection of alirocumab 75 mg administered Q4W from Week 14 until switch to Cohort 2 dosage including dose adjustment to body weight as required, then Cohort 2 dosage: if body weight was still \< 50 kg, participants received SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was \> = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130.

    Drug: alirocumab SAR236553 (REGN727) · Drug: statins · Drug: ezetimibe · Drug: cholestyramine · Drug: fenofibrate · Drug: omega-3 fatty acids · Drug: nicotinic acid

  • Experimental
    Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg

    Period 1: Participants with body weight \>= 50 kg received SC injection of alirocumab 150 mg administered Q4W up to Week 8 added to LMT. Period 2: Participants with body weight \>= 50 kg received SC injection of alirocumab 150 mg administered Q4W from Week 14 until switch to Cohort 2 dosage then SC injection of alirocumab 75 mg administered Q2W until Week 130.

    Drug: alirocumab SAR236553 (REGN727) · Drug: statins · Drug: ezetimibe · Drug: cholestyramine · Drug: fenofibrate · Drug: omega-3 fatty acids · Drug: nicotinic acid

  • Experimental
    Cohort 4 - Alirocumab 150 mg Q4W: <50 kg

    Period 1: Participants with body weight \< 50 kg received SC injection of alirocumab 150 mg administered Q4W up to 12 weeks added to LMT. Period 2: Participants with body weight \< 50 kg received SC injection of Alirocumab 150 mg administered Q4W from Week 12 until Week 48.

    Drug: alirocumab SAR236553 (REGN727) · Drug: statins · Drug: ezetimibe · Drug: cholestyramine · Drug: fenofibrate · Drug: omega-3 fatty acids · Drug: nicotinic acid

  • Experimental
    Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg

    Period 1: Participants with body weight \>= 50 kg received SC injection of alirocumab 300 mg administered Q4W up to 12 weeks added to LMT. Period 2: Participants with body weight \>= 50 kg received SC injection of alirocumab 300 mg administered Q4W from Week 12 until Week 48.

    Drug: alirocumab SAR236553 (REGN727) · Drug: statins · Drug: ezetimibe · Drug: cholestyramine · Drug: fenofibrate · Drug: omega-3 fatty acids · Drug: nicotinic acid

Interventions

  • Pharmaceutical form: solution Route of administration: subcutaneous injection

    Also known as: Praluent

  • Pharmaceutical form: tablet Route of administration: oral

  • Pharmaceutical form:tablet Route of administration: oral

  • Pharmaceutical form:tablet Route of administration: oral

  • Pharmaceutical form: tablet Route of administration: oral

  • Pharmaceutical form: tablet Route of administration: oral

  • Pharmaceutical form: tablet Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8

    Percent change in calculated LDL-C was defined as 100\*(calculated LDL-C value at Week 8 - calculated LDL-C value at baseline)/calculated LDL-C value at baseline. All available baseline and post-baseline calculated LDL-C value during the OLDFI efficacy treatment period \& within one of the analysis windows up to Week 8 were used in the model. OLDFI efficacy treatment period was defined as the period from first investigational medicinal product (IMP) injection to last OLDFI IMP injection + 21 days(for Cohorts 1 \& 2) or +35 days (for Cohorts 3 \& 4). Adjusted Least-squares (LS) mean \& standard error (SE) at Week 8 were obtained from mixed-effect model with repeated measures (MMRM) analysis, with fixed categorical effects of alirocumab dose/dose regimen (30 mg Q2W \[\<50 kg\], 40 mg Q2W \[\<50 kg\], 50 mg Q2W \[\>=50 kg\], 75 mg Q2W \[\>=50 kg\], 75 mg Q4W \[\<50 kg\],150 mg Q4W \[\>=50 kg\], 150 mg Q4W \[\<50 kg\] and 300 mg Q4W (\[\>=50 kg\] dose), time point \& dose/dose regimen-by-time point interaction.

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Absolute Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8

    Absolute change in LDL-C was calculated by subtracting baseline value from Week 8 value. Adjusted LS means and SE were obtained using MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction.

    Time frame: Baseline, Week 8

  2. Percentage of Participants Achieving Calculated Low Density Lipoprotein Cholesterol (LDL-C) <130 mg/dL (3.37 mmol/L) at Week 8

    Combined estimate for percentage of participants was obtained by averaging out all the imputed percentage of participants reaching the level of interest. A two-step multiple imputation procedure was used to address missing values in the mITT population in the two steps respectively; with number of imputations = 1000. In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.

    Time frame: At Week 8

  3. Percentage of Participants Achieving Calculated LDL-C <110 mg/dL (2.84 mmol/L) at Week 8

    Combined estimate for percentage of participants was obtained by averaging out all the imputed percentage of participants reaching the level of interest. A two-step multiple imputation procedure was used to address missing values in the mITT population in the two steps respectively; with number of imputations = 1000. In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.

    Time frame: At Week 8

  4. Percent Change From Baseline in Calculated LDL-C at Week 12: Cohort 4

    Adjusted LS means and standard error at Week 12 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction.

    Time frame: Baseline, Week 12

  5. Percent Change From Baseline in Apolipoprotein (Apo) B at Week 8

    Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline value and post-baseline values in at least one of the analysis windows used in the model.

    Time frame: Baseline, Week 8

  6. Percent Change From Baseline in Non-High Density Lipoprotein (HDL-C) at Week 8

    Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baselines value and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

    Time frame: Baseline, Week 8

  7. Percent Change From Baseline in Total Cholesterol (Total-C) at Week 8

    Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

    Time frame: Baseline, Week 8

  8. Percent Change From Baseline in Lipoprotein(a) at Week 8

    Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population in the two steps respectively (with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.

    Time frame: Baseline, Week 8

  9. Percent Change From Baseline in Fasting Triglyceride at Week 8

    Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population (in the two steps respectively; with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.

    Time frame: Baseline, Week 8

  10. Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 8

    Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

    Time frame: Baseline, Week 8

  11. Percent Change From Baseline in Apolipoprotein A-1 at Week 8

    Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

    Time frame: Baseline, Week 8

  12. Absolute Change From Baseline in Apolipoprotein B at Week 8

    Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

    Time frame: Baseline, Week 8

  13. Absolute Change From Baseline in Non-High-Density Lipoprotein (Non-HDL-C) at Week 8

    Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

    Time frame: Baseline, Week 8

  14. Absolute Change From Baseline in Total Cholesterol (Total-C) at Week 8

    Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

    Time frame: Baseline, Week 8

  15. Absolute Change From Baseline in Lipoprotein(a) at Week 8

    Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population (in the two steps respectively; with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.

    Time frame: Baseline, Week 8

  16. Absolute Change From Baseline in HDL-C at Week 8

    Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

    Time frame: Baseline, Week 8

  17. Absolute Change From Baseline in Fasting Triglyceride at Week 8

    Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population (in the two steps respectively; with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.

    Time frame: Baseline, Week 8

  18. Absolute Change From Baseline in Apolipoprotein A-1 at Week 8

    Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

    Time frame: Baseline, Week 8

  19. Absolute Change From Baseline in Ratio Apolipoprotein B/Apolipoprotein A-1 at Week 8

    Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

    Time frame: Baseline, Week 8

07

Results

Posted Sep 6, 2019

Participant flow

The study was conducted at 16 sites in 10 countries. Overall 63 participants were screened between 15 September 2016 and 13 June 2018, of whom 21 participants were screen failures. Screen failures were mainly due to exclusion criteria met.

12 Weeks Open-Label Dose Finding Period
Participant flow — 12 Weeks Open-Label Dose Finding Period
MilestoneCohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Started46466565
Treated46466565
Completed46466565
Not completed00000000
130 Weeks Open-Label Extension Period
Participant flow — 130 Weeks Open-Label Extension Period
MilestoneCohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Started36466565
Treated36466554
Completed33466554
Not completed03000011
Withdrew: Adverse event01000000
Withdrew: Included but not treated00000011
Withdrew: Other than specified02000000

Outcome measures

PrimaryPercent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8

Percent change in calculated LDL-C was defined as 100\*(calculated LDL-C value at Week 8 - calculated LDL-C value at baseline)/calculated LDL-C value at baseline. All available baseline and post-baseline calculated LDL-C value during the OLDFI efficacy treatment period \& within one of the analysis windows up to Week 8 were used in the model. OLDFI efficacy treatment period was defined as the period from first investigational medicinal product (IMP) injection to last OLDFI IMP injection + 21 days(for Cohorts 1 \& 2) or +35 days (for Cohorts 3 \& 4). Adjusted Least-squares (LS) mean \& standard error (SE) at Week 8 were obtained from mixed-effect model with repeated measures (MMRM) analysis, with fixed categorical effects of alirocumab dose/dose regimen (30 mg Q2W \[\<50 kg\], 40 mg Q2W \[\<50 kg\], 50 mg Q2W \[\>=50 kg\], 75 mg Q2W \[\>=50 kg\], 75 mg Q4W \[\<50 kg\],150 mg Q4W \[\>=50 kg\], 150 mg Q4W \[\<50 kg\] and 300 mg Q4W (\[\>=50 kg\] dose), time point \& dose/dose regimen-by-time point interaction.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8
percent changeCohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8-41.1 ± 12.6-7.9 ± 10.3-40.6 ± 13.2-49.8 ± 10.6-17.5 ± 10.34.0 ± 11.2-31.9 ± 10.3-59.8 ± 11.2
SecondaryAbsolute Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8

Absolute change in LDL-C was calculated by subtracting baseline value from Week 8 value. Adjusted LS means and SE were obtained using MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · milligram per deciliter (mg/dL)
Absolute Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8
milligram per deciliter (mg/dL)Cohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Absolute Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8-83.7 ± 19.5-27.6 ± 15.9-55.5 ± 20.8-88.3 ± 16.5-32.4 ± 15.90.1 ± 17.4-55.9 ± 15.9-104.3 ± 17.4
SecondaryPercentage of Participants Achieving Calculated Low Density Lipoprotein Cholesterol (LDL-C) <130 mg/dL (3.37 mmol/L) at Week 8

Combined estimate for percentage of participants was obtained by averaging out all the imputed percentage of participants reaching the level of interest. A two-step multiple imputation procedure was used to address missing values in the mITT population in the two steps respectively; with number of imputations = 1000. In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Calculated Low Density Lipoprotein Cholesterol (LDL-C) <130 mg/dL (3.37 mmol/L) at Week 8
percentage of participantsCohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Percentage of Participants Achieving Calculated Low Density Lipoprotein Cholesterol (LDL-C) <130 mg/dL (3.37 mmol/L) at Week 8100.033.397.683.033.320.066.780.0
SecondaryPercentage of Participants Achieving Calculated LDL-C <110 mg/dL (2.84 mmol/L) at Week 8

Combined estimate for percentage of participants was obtained by averaging out all the imputed percentage of participants reaching the level of interest. A two-step multiple imputation procedure was used to address missing values in the mITT population in the two steps respectively; with number of imputations = 1000. In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Calculated LDL-C <110 mg/dL (2.84 mmol/L) at Week 8
percentage of participantsCohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Percentage of Participants Achieving Calculated LDL-C <110 mg/dL (2.84 mmol/L) at Week 80.00.093.465.716.720.066.780.0
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12: Cohort 4

Adjusted LS means and standard error at Week 12 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12: Cohort 4
percent changeCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Percent Change From Baseline in Calculated LDL-C at Week 12: Cohort 4-29.7 ± 6.9-49.2 ± 7.5
SecondaryPercent Change From Baseline in Apolipoprotein (Apo) B at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline value and post-baseline values in at least one of the analysis windows used in the model.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 8
percent changeCohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 8-38.4 ± 12.8-9.7 ± 9.1-36.4 ± 12.8-40.1 ± 9.9-12.6 ± 9.1-0.9 ± 9.9-27.2 ± 9.1-51.4 ± 9.9
SecondaryPercent Change From Baseline in Non-High Density Lipoprotein (HDL-C) at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baselines value and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-High Density Lipoprotein (HDL-C) at Week 8
percent changeCohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Percent Change From Baseline in Non-High Density Lipoprotein (HDL-C) at Week 8-39.6 ± 11.9-7.1 ± 9.7-39.7 ± 12.5-43.9 ± 10.0-14.4 ± 9.73.2 ± 10.7-31.5 ± 9.7-54.6 ± 10.7
SecondaryPercent Change From Baseline in Total Cholesterol (Total-C) at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 8
percent changeCohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 8-29.0 ± 9.7-4.1 ± 7.9-28.6 ± 10.1-34.2 ± 8.1-10.7 ± 7.95.2 ± 8.6-24.0 ± 7.9-41.8 ± 8.6
SecondaryPercent Change From Baseline in Lipoprotein(a) at Week 8

Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population in the two steps respectively (with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.

Time frame:
Baseline, Week 8
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein(a) at Week 8
percent changeCohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Percent Change From Baseline in Lipoprotein(a) at Week 84.5 ± 21.1-26.9 ± 11.61.5 ± 15.1-25.2 ± 14.42.2 ± 10.5-7.7 ± 11.40.1 ± 10.2-7.7 ± 11.1
SecondaryPercent Change From Baseline in Fasting Triglyceride at Week 8

Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population (in the two steps respectively; with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.

Time frame:
Baseline, Week 8
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglyceride at Week 8
percent changeCohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Percent Change From Baseline in Fasting Triglyceride at Week 8-0.4 ± 19.6-4.0 ± 16.0-7.4 ± 28.414.5 ± 19.019.3 ± 16.0-3.1 ± 17.5-32.1 ± 16.0-7.1 ± 17.5
SecondaryPercent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · percent change
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 8
percent changeCohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 89.7 ± 7.116.5 ± 5.814.7 ± 7.710.6 ± 6.15.2 ± 5.813.8 ± 6.44.5 ± 5.82.8 ± 6.4
SecondaryPercent Change From Baseline in Apolipoprotein A-1 at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein A-1 at Week 8
percent changeCohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Percent Change From Baseline in Apolipoprotein A-1 at Week 84.4 ± 7.214.8 ± 5.110.7 ± 7.21.8 ± 5.68.9 ± 5.17.4 ± 5.65.8 ± 5.17.2 ± 5.6
SecondaryAbsolute Change From Baseline in Apolipoprotein B at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in Apolipoprotein B at Week 8
mg/dLCohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Absolute Change From Baseline in Apolipoprotein B at Week 8-51.7 ± 15.8-18.5 ± 11.1-35.3 ± 15.8-53.4 ± 12.2-15.3 ± 11.1-5.4 ± 12.2-34.2 ± 11.1-63.5 ± 12.2
SecondaryAbsolute Change From Baseline in Non-High-Density Lipoprotein (Non-HDL-C) at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in Non-High-Density Lipoprotein (Non-HDL-C) at Week 8
mg/dLCohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Absolute Change From Baseline in Non-High-Density Lipoprotein (Non-HDL-C) at Week 8-86.1 ± 20.8-28.7 ± 17.0-62.7 ± 22.1-88.5 ± 17.6-29.5 ± 17.0-0.6 ± 18.6-63.1 ± 17.0-106.4 ± 18.6
SecondaryAbsolute Change From Baseline in Total Cholesterol (Total-C) at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in Total Cholesterol (Total-C) at Week 8
mg/dLCohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Absolute Change From Baseline in Total Cholesterol (Total-C) at Week 8-80.1 ± 21.4-20.8 ± 17.5-57.1 ± 22.8-84.4 ± 18.1-27.2 ± 17.55.3 ± 19.1-60.7 ± 17.5-105.1 ± 19.1
SecondaryAbsolute Change From Baseline in Lipoprotein(a) at Week 8

Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population (in the two steps respectively; with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · gram/Liter (g/L)
Absolute Change From Baseline in Lipoprotein(a) at Week 8
gram/Liter (g/L)Cohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Absolute Change From Baseline in Lipoprotein(a) at Week 80.003 ± 0.022-0.021 ± 0.0170.007 ± 0.073-0.025 ± 0.0200.023 ± 0.018-0.031 ± 0.019-0.002 ± 0.017-0.120 ± 0.020
SecondaryAbsolute Change From Baseline in HDL-C at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in HDL-C at Week 8
mg/dLCohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Absolute Change From Baseline in HDL-C at Week 85.9 ± 3.47.7 ± 2.85.5 ± 3.74.9 ± 2.92.4 ± 2.85.9 ± 3.12.2 ± 2.81.2 ± 3.1
SecondaryAbsolute Change From Baseline in Fasting Triglyceride at Week 8

Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population (in the two steps respectively; with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · mmol/L
Absolute Change From Baseline in Fasting Triglyceride at Week 8
mmol/LCohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Absolute Change From Baseline in Fasting Triglyceride at Week 8-0.121 ± 0.193-0.076 ± 0.1570.168 ± 0.2260.111 ± 0.1880.117 ± 0.157-0.045 ± 0.172-0.402 ± 0.157-0.107 ± 0.172
SecondaryAbsolute Change From Baseline in Apolipoprotein A-1 at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in Apolipoprotein A-1 at Week 8
mg/dLCohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Absolute Change From Baseline in Apolipoprotein A-1 at Week 84.0 ± 9.317.7 ± 6.511.3 ± 9.3-0.4 ± 7.210.5 ± 6.58.0 ± 7.27.5 ± 6.511.0 ± 7.2
SecondaryAbsolute Change From Baseline in Ratio Apolipoprotein B/Apolipoprotein A-1 at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · ratio (Apo B/Apo A-1)
Absolute Change From Baseline in Ratio Apolipoprotein B/Apolipoprotein A-1 at Week 8
ratio (Apo B/Apo A-1)Cohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kg
Absolute Change From Baseline in Ratio Apolipoprotein B/Apolipoprotein A-1 at Week 8-0.363 ± 0.123-0.262 ± 0.087-0.370 ± 0.123-0.402 ± 0.096-0.190 ± 0.087-0.086 ± 0.096-0.282 ± 0.087-0.473 ± 0.096

Adverse events

Collected over All Adverse Events (AEs) were collected from the time of first dose of IMP up to the end of study (Week 152) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg0/4 (0%)0/4 (0%)4/4 (100%)
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg0/6 (0%)0/6 (0%)5/6 (83.3%)
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg0/4 (0%)0/4 (0%)1/4 (25%)
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg0/6 (0%)0/6 (0%)4/6 (66.7%)
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg0/6 (0%)0/6 (0%)5/6 (83.3%)
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg0/5 (0%)0/5 (0%)3/5 (60%)
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg0/6 (0%)0/6 (0%)3/6 (50%)
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg0/5 (0%)0/5 (0%)4/5 (80%)
Alirocumab 40 Q2W Post-switch0/10 (0%)0/10 (0%)7/10 (70%)
Alirocumab 75 Q2W Post-switch0/18 (0%)0/18 (0%)9/18 (50%)
Most frequent other events
Showing 10 of 70
Most frequent other events
EventCohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kgAlirocumab 40 Q2W Post-switchAlirocumab 75 Q2W Post-switch
DiarrhoeaGastrointestinal disorders0/42/60/40/61/60/51/61/50/100/18
NasopharyngitisInfections and infestations1/42/60/41/60/61/50/60/51/102/18
Gastroenteritis ViralInfections and infestations1/40/60/40/61/60/50/60/53/101/18
Influenza Like IllnessGeneral disorders1/41/60/40/60/60/50/61/51/100/18
Ear InfectionInfections and infestations1/40/60/41/61/60/50/60/51/101/18
Infectious MononucleosisInfections and infestations1/40/60/40/60/60/50/60/50/100/18
PharyngitisInfections and infestations0/40/61/40/60/60/50/60/50/100/18
FallInjury, poisoning and procedural complications1/41/60/40/61/60/50/60/50/100/18
Ligament SprainInjury, poisoning and procedural complications1/40/60/41/60/60/50/60/50/102/18
Traumatic HaematomaInjury, poisoning and procedural complications1/40/60/40/60/60/50/60/50/100/18

Baseline characteristics

Analysis was performed on safety population that included population who did actually received at least one dose or part of a dose of the open-label investigational medicinal product (IMP). Participants were analyzed according to the dose of alirocumab actually received.

Age, Continuous
Age, Continuous(years)Cohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kgTotal
Mean11.0 ± 2.013.8 ± 2.711.3 ± 2.214.3 ± 2.39.8 ± 1.913.8 ± 1.611.3 ± 2.213.6 ± 2.112.4 ± 2.6
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kgTotal
Female2422331219
Male2224325323
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kgTotal
Black or African American000000022
Black or African American/White000010001
White4646556339
Low Density Lipoprotein Cholesterol (LDL-C)
Low Density Lipoprotein Cholesterol (LDL-C)(millimoles per litre (mmol/L))Cohort 1 - Alirocumab 30 mg Q2W: <50 kgCohort 1 - Alirocumab 50 mg Q2W: >=50 kgCohort 2 - Alirocumab 40 mg Q2W: <50 kgCohort 2 - Alirocumab 75 mg Q2W: >=50 kgCohort 3 - Alirocumab 75 mg Q4W: <50 kgCohort 3 - Alirocumab 150 mg Q4W: >=50 kgCohort 4 - Alirocumab 150 mg Q4W: <50 kgCohort 4 - Alirocumab 300 mg Q4W: >=50 kgTotal
Mean5.169 ± 0.7364.339 ± 1.2003.596 ± 0.6304.510 ± 1.0524.337 ± 1.1474.642 ± 1.2725.100 ± 1.1364.641 ± 0.9264.6 ± 1.1
08

Study locations

16 sites
  • Investigational Site Number 8400002
    Saint Louis, Missouri 63110, United States
  • Investigational Site Number 8400005
    Charlotte, North Carolina 28204, United States
  • Investigational Site Number 8400001
    Cincinnati, Ohio 45229, United States
  • Investigational Site Number 1240001
    Quebec, G1V 4W2, Canada
  • Investigational Site Number 2030001
    Brno, 62500, Czechia
  • Investigational Site Number 2030003
    Praha 5 - Motol, 15006, Czechia
  • Investigational Site Number 2030002
    Zlin, 76275, Czechia
  • Investigational Site Number 2500001
    Bron Cedex, 69677, France
  • Investigational Site Number 5280001
    Amsterdam, 1105AZ, Netherlands
  • Investigational Site Number 5780001
    Oslo, Norway
  • Investigational Site Number 6430001
    Kemerovo, 650002, Russian Federation
  • Investigational Site Number 6430004
    Saint-Petersburg, 194100, Russian Federation
  • Investigational Site Number 7100001
    Parow, 7500, South Africa
  • Investigational Site Number 7240004
    A Coruna, 15001, Spain
  • Investigational Site Number 7240001
    Madrid, 28009, Spain
  • Investigational Site Number 7520001
    Stockholm, 171 76, Sweden
09

References and documents

Publications

  • Daniels S, Caprio S, Chaudhari U, Manvelian G, Baccara-Dinet MT, Brunet A, Scemama M, Loizeau V, Bruckert E. PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study. J Clin Lipidol. 2020 May-Jun;14(3):322-330.e5. doi: 10.1016/j.jacl.2020.03.001. Epub 2020 Mar 28. Erratum In: J Clin Lipidol. 2020 Sep - Oct;14(5):741. doi: 10.1016/j.jacl.2020.08.011. PubMed 32331936 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Sep 2018, 23 months.

Results were first posted in Sep 2019, 11 months after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 23 months is above that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2016
First posted
Sep 7, 2016
StartActual
Sep 15, 2016
Primary completionActual
Sep 13, 2018
CompletionActual
Feb 22, 2019
Results first posted
Sep 6, 2019
Last update
Sep 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02890992
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 7, 2016
Start date
Sep 15, 2016
Primary completion
Sep 13, 2018
Completion
Feb 22, 2019
Results posted
Sep 6, 2019
Last update
Sep 6, 2019

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alirocumab · Statins · Ezetimibe · Cholestyramine Resin · Fenofibrate · Omega-3 fatty acid · Niacin

Start the discussion